Abstracts tagged "abatacept and anti-citrullinated protein/peptide antibodies (ACPA)"

Abstract Number: 1386 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Leslie Harrold¹, Ying Shan ², Sabrina Rebello ², Lin Guo ², Sean Connolly ³, Joe Zhuo ³, Sheila Kelly ³ and Thomas Lehman ³, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: In a US national observational study conducted in a clinical practice setting, patients who were positive (+) for anti-cyclic citrullinated peptide (CCP) antibodies at…
Abstract Number: 551 • 2015 ACR/ARHP Annual Meeting
Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
R Alten¹, HG Nüßlein², M Galeazzi³, H-M Lorenz⁴, X Mariette⁵, A Cantagrel⁶, M Chartier⁷, G Desachy⁸, C Poncet⁹, C Rauch¹⁰ and M Le Bars¹¹, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Erlangen, Nürnberg, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵Université Paris-Sud, Paris, France, ⁶Purpan Hospital, Toulouse, France, ⁷Chiltern International, Neuilly, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Docs International, Nanterre, France, ¹⁰Bristol-Myers Squibb, Munich, Germany, ¹¹Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In a recent meta-analysis, neither rheumatoid factor (RF) nor anti-cyclic citrullinated peptide (anti-CCP) antibody status were associated with clinical response to treatment with anti-TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].